Clinical trial
Study Of An FDA-approved Drug As Additional Therapy In Patients With…
NCT00086593 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00086593 |
|---|---|
| Title | Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects With Schizophrenia |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | lamotrigine |
| Enrollment | 209 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Jul 8, 2004 |
| Last update posted | Oct 7, 2016 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: